Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company designing small molecule compounds targeted at various diseases. It utilizes the chemical simulation computational platform built by co-founder Schrödinger Inc., which incorporates artificial intelligence and machine learning, and co-develops drugs by partnering with pharma companies. Its pipeline includes programs in metabolic diseases, cancer, and immune-inflammatory disorders. 

As of March 2024, the company was developing five targets, of which one is in the clinical stage, two are in the preclinical stage, and others remain at a discovery stage. The company initiated investigational new drug (IND)-enabling studies on two novel agents in 2022.

Takeda Pharmaceuticals acquired Nimbus Therapeutics’s fully owned subsidiary, Nimbus Lakshmi, and its tyrosine kinase 2 (TYK2) (intracellular enzyme) program in February 2023 . Following the acquisition, Nimbus’ drug candidate, NDI-034858, for psoriasis was renamed to “TAK-279.” 

Key customers and partnerships

Nimbus Therapeutics’  pharma partners include Roche’s Genentech, Celgene, and Gilead. In December 2023 , Nimbus Therapeutics partnered with Anagenex to discover small-molecule drugs for various complex targets. Further, in October 2022, the company partnered with Eli Lilly to progress the development of novel targeted therapies that activate AMPK to potentially treat a broad range of metabolic disorders.

Funding and financials

In September 2023, the company raised USD 210 million in a private funding round co-led by GV (Google Ventures) in September 2023 to advance Nimbus Therapeutics' pipeline of drugs for various disorders.